Change in Paraprotein from Baseline

  • The majority of patients had reductions in paraprotein from baseline
    • 40 patients (38%) had reductions >50%
    • 17 patients (16%) had reductions >90%

Response Rates

n (%, 95% CI)
Overall response ratea 31 (29.2, 20.8-38.9)
Clinical benefit rateb 36 (34.0, 25.0-43.8)
Stringent complete response 3 (2.8, 0.6-8.0)
Complete response -
Very good partial response 10 (9.4, 4.6-16.7)
Partial response 18 (17.0, 10.4-25.5)
Minimal response 5 (4.7, 1.5-10.7)
Stable disease 46 (43.4, 33.8-53.4)
Progressive disease 18 (17.0, 10.4-25.5)
Not evaluable 6 (5.7, 2.1-11.9)

a Defined as stringent complete response + complete response + very good partial response + partial response
b Defined as overall response rate + minimal response

Depth and Duration of Response

  • The median duration of follow-up was 9.3 months (0.5-14.4)
  • The median time to first response was 1.0 month (0.9-5.6)
  • The median duration of response was 7.4 months (95% CI, 5.5-not estimable)
  • Initial responses deepened with continued daratumumab treatment in many patients

Patient Subgroups

  • Responses were noted in pre-specified subgroups irrespective of previous lines of therapy and refractory status

Progression-free and Overall Survival

  • Median follow-up of 9.3 months, 29 of 31 responders are still alive
  • The 1-year survival rate was 64.8% (95% CI, 51.2-75.5)
  • At median follow-up of 14.7 months, median OS was 17.5 months (95% CI, 13.7–NE)*

* Voorhees P, et al. Poster presented at: 2015 ASH Meeting; September 17-19, 2015; Chicago, IL, USA.

Prev
Next